Related references
Note: Only part of the references are listed.Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Epidemiology of Pancreatic and Periampullary Cancer
Prabin Thapa
INDIAN JOURNAL OF SURGERY (2015)
Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy
Sarah B. Fisher et al.
CANCER (2013)
An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma
Sarah B. Fisher et al.
CANCER (2013)
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Matias E. Valsecchi et al.
BMC CANCER (2012)
Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection
Shishir K. Maithel et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
Lars Petter Jordheim et al.
LANCET ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma
H. Akita et al.
ONCOGENE (2009)
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses
A. Sultana et al.
BRITISH JOURNAL OF CANCER (2008)
Platinum resistance: The role of DNA repair pathways
Lainie P. Martin et al.
CLINICAL CANCER RESEARCH (2008)
ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer
Zhao-Hui Huang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
Lucy Gossage et al.
CANCER TREATMENT REVIEWS (2007)
Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy
Koichi Azuma et al.
CANCER SCIENCE (2007)
Molecular predictors of chemotherapy response in non-small-cell lung cancer
Jhanelle Gray et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
Y Shirota et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
